Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02942004




Registration number
NCT02942004
Ethics application status
Date submitted
20/10/2016
Date registered
21/10/2016
Date last updated
28/01/2022

Titles & IDs
Public title
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
Scientific title
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects With Severe Postpartum Depression and Adult Female Subjects With Moderate Postpartum Depression
Secondary ID [1] 0 0
547-PPD-202 B
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Postpartum Depression 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Depression
Reproductive Health and Childbirth 0 0 0 0
Childbirth and postnatal care

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - SAGE-547 60 µg/kg/h
Treatment: Drugs - SAGE-547 90 µg/kg/h

Placebo Comparator: Placebo - Participants received infusion rates equivalent to either the 60 micrograms per kilogram per hour (µg/kg/h) or 90 µg/kg/h group.

Experimental: SAGE-547 60 µg/kg/h - Participants received a 4-hour titration period of 30 µg/kg/h (0 to 4 hours), then 60 µg/kg/h (4 to 56 hours), followed by a taper to 30 µg/kg/h (56 to 60 hours).

Experimental: SAGE-547 90 µg/kg/h - Participants received a 4-hour dose titration period of 30 µg/kg/h (0 to 4 hours), then 60 µg/kg/h (4 to 24 hours), then 90 µg/kg/h (24 to 52 hours), followed by a taper to 60 µg/kg/h (52 to 56 hours), and 30 µg/kg/h (56 to 60 hours).


Treatment: Drugs: Placebo
Intravenous infusion of matching placebo for either SAGE-547 60 µg/kg/h or 90 µg/kg/h.

Treatment: Drugs: SAGE-547 60 µg/kg/h
Intravenous infusion of SAGE-547.

Treatment: Drugs: SAGE-547 90 µg/kg/h
Intravenous infusion of SAGE-547.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline at 60 Hours in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score
Timepoint [1] 0 0
Baseline, Hour 60
Secondary outcome [1] 0 0
Change From Baseline in HAM-D Total Score at Day 30
Timepoint [1] 0 0
Baseline, Day 30
Secondary outcome [2] 0 0
Change From Baseline in HAM-D Total Score
Timepoint [2] 0 0
Baseline, Hours 2, 4, 8, 12, 24, 36, 48, 72, and Days 7, 14, and 21
Secondary outcome [3] 0 0
Percentage of Participants With HAM-D Response
Timepoint [3] 0 0
Hour 60, Days 7 and 30
Secondary outcome [4] 0 0
Percentage of Participants With HAM-D Remission
Timepoint [4] 0 0
Hour 60, Days 7 and 30
Secondary outcome [5] 0 0
Change From Baseline in HAM-D Bech 6 Subscale
Timepoint [5] 0 0
Baseline, Hour 60, Days 7 and 30
Secondary outcome [6] 0 0
Change From Baseline in HAM-D Individual Item Scores
Timepoint [6] 0 0
Baseline, Hour 2, Hour 4, Hour 8, Hour 12, Hour 24, Hour 36, Hour 48, Hour 60, Hour 72 and Days 7, 14, 21 and 30
Secondary outcome [7] 0 0
Change From Baseline at Key Time Points in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
Timepoint [7] 0 0
Baseline, Hour 60, Days 7 and 30
Secondary outcome [8] 0 0
Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response
Timepoint [8] 0 0
Hour 60, Days 7 and 30
Secondary outcome [9] 0 0
Change From Baseline in the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score
Timepoint [9] 0 0
Baseline, Hour 60, Days 7, 14, 21 and 30
Secondary outcome [10] 0 0
Percentage of Participants With Treatment-Emergent Adverse Events
Timepoint [10] 0 0
Up to approximately 37 days.
Secondary outcome [11] 0 0
Time to Change in Antidepressant Medication
Timepoint [11] 0 0
Up to approximately 37 days.

Eligibility
Key inclusion criteria
Key

- Participants must have ceased lactating at screening; or if still lactating or
actively breastfeeding at screening, agreed to temporarily cease giving breastmilk to
their infant(s) from just prior to receiving study drug through nine days (Day 12)
after the end of the infusion

- Participants had a major depressive episode that began no earlier than the third
trimester and no later than the first 4 weeks following delivery, as diagnosed by
Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)

- Participant had a HAM-D total score of =26 at screening and Day 1 (prior to dosing)

- Participant was =6 months postpartum at screening

- Participant was amenable to IV therapy

Key
Minimum age
18 Years
Maximum age
45 Years
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
- Active psychosis

- Attempted suicide associated with index case of postpartum depression

- Medical history of bipolar disorders, schizophrenia, and/or schizoaffective disorder.

Note: Other protocol-defined inclusion/exclusion criteria applied.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
19/10/2017
Sample size
Target
Accrual to date
Final
138
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Mississippi
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Utah

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Sage Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up
to 90 micrograms per kilogram per hour (µg/kg/h) for 60 hours reduces depressive symptoms in
participants with severe postpartum depression (PPD) compared to placebo injection as
assessed by the change from baseline in Hamilton Rating Scale for Depression (HAM-D) total
score.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02942004
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
Helen Colquhoun, MD
Address 0 0
Sage Therapeutics
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries